Eli Lilly (LLY 1.80%) and Novo Nordisk (NVO 2.76%) benefit from innovative treatments for obesity and diabetes.
*Stock prices used were the afternoon prices of Jan. 5, 2025. The video was published on Jan. 7, 2025.
Free Article
You're reading a free article with opinions that may differ from The Motley Fool's Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
Best Healthcare Stock to Buy: Eli Lilly vs. Novo Nordisk
By Parkev Tatevosian, CFA
–
Jan 8, 2025 at 10:28AM
NYSE: LLY
Eli Lilly
Market Cap
$747B
Today's Change
(1.80%) $13.93
Current Price
$787.22
Price as of January 8, 2025, 4:00 p.m. ET
Parkev Tatevosian, CFA has no position in any of the stocks mentioned. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy.Parkev Tatevosian is an affiliate of The Motley Fool and may be compensated for promoting its services. If you choose to subscribe through his link, he will earn some extra money that supports his channel. His opinions remain his own and are unaffected by The Motley Fool.
Related Articles
This Promising New Alzheimer's Study Could Unlock a Massive Growth Opportunity for Novo Nordisk and Eli Lilly
Will This Major Pharmaceutical Stock Announce a Stock Split in 2025?
Billionaire Philippe Laffont Is Selling Artificial Intelligence Champion Nvidia and Piling Into These Two Industry Leaders
Is Eli Lilly Stock a Buy?
2 Pharmaceutical Growth Stocks to Buy Now and Hold for Decades
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.